Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session - Genitourinary tumours, non prostate

3575 - Pembrolizumab for High-Risk (HR) Non–Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guérin (BCG): Phase 2 KEYNOTE-057 Trial

Date

20 Oct 2018

Session

Proffered paper session - Genitourinary tumours, non prostate

Presenters

Ronald de Wit

Citation

Annals of Oncology (2018) 29 (suppl_8): viii303-viii331. 10.1093/annonc/mdy283

Authors

R. de Wit1, G.S. Kulkarni2, E. Uchio3, E.A. Singer4, L. Krieger5, P. Grivas6, D. Bajorin7, H.K. Seo8, L. Mourey9, A. Kamat10, H. Nishiyama11, E. Kapadia12, K. Nam12, T. Frenkl12, A. Balar13

Author affiliations

  • 1 Medical Oncology, Erasmus MC Cancer Institute, 3075 EA - Rotterdam/NL
  • 2 Surgery And Surgical oncology, UHN Princess Margaret Cancer Centre, m5g 2m9 - Toronto/CA
  • 3 Urology, UC Irvine Health, Orange/US
  • 4 Urology, Rutgers Cancer Institute of New Jersey, New Brunswick/US
  • 5 Medical Oncology, Royal North Shore Hospital, Northern Cancer Institute, St. Leonards/AU
  • 6 Medical Oncology, University of Washington, Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle/US
  • 7 Medical Oncology, Memorial Sloan Kettering Cancer Center, 10022 - New York/US
  • 8 Urology, National Cancer Center, 410-769 - Goyang/KR
  • 9 Medical Oncology, Institut Universitaire du Cancer Toulouse Oncopole, 31059 - Toulouse/FR
  • 10 Urology, The University of Texas MD Anderson Cancer Center, Houston/US
  • 11 Urology, University of Tsukuba, Tsukuba/JP
  • 12 Medical Oncology, Merck & Co., Inc., 07033 - Kenilworth/US
  • 13 Medicine, NYU Langone Medical Center, 10016 - New York/US
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3575

Background

Activation of the PD-1 pathway has been implicated in resistance to BCG therapy. Pembrolizumab (pembro), a checkpoint inhibitor with significant activity in patients (pts) with metastatic urothelial carcinoma, was evaluated in this population. KEYNOTE-057 (NCT02625961) is a single-arm phase 2 study of the efficacy and safety of pembro in pts with HR, BCG-unresponsive NMIBC. Preliminary results for cohort A (carcinoma in situ [CIS] or CIS plus papillary tumor) are presented.

Methods

Eligible pts had histologically confirmed high-grade BCG-unresponsive NMIBC, including CIS alone or combination of CIS and papillary disease (cohort A), had been treated with adequate BCG therapy (at least 5/6 induction instillations and 2/3 maintenance therapy instillations), and were unable or unwilling to undergo radical cystectomy. Pts received pembro 200 mg Q3W for 24 mo or until recurrence, progression, or unacceptable toxicity. The primary end point for cohort A was complete response (CR); key secondary end points were safety and duration of response. Pts found to have HR NMIBC or progressive disease during treatment were required to discontinue.

Results

At the time of data cutoff, 101 pts were enrolled in cohort A. Median follow-up was 9.4 mo (range 0.2-21.2). At mo 3, CR rate by central assessment was 36.5% (95% CI 26.3-47.6) in 85 evaluable pts. Among the 31 pts with CR at mo 3, median duration of CR was 8.1 mo (range 0+ to 13.7+). Estimated proportion of pts with response duration ≥6 mo was 85.6%. Treatment-related adverse events (AEs) occurred in 54 pts (55.7%); most common (≥5%) were diarrhea (9.3%), pruritus (9.3%), fatigue (7.2%), hypothyroidism (5.2%), maculopapular rash (5.2%), and arthralgia (5.2%). Treatment-related grade 3-5 AEs occurred in 11 pts (11.3%); 1 death was considered treatment related. Immune-mediated AEs occurred in 15 pts (15.5%) and were grade 3/4 in 2 pts (2.1%).

Conclusions

Pembro exhibits encouraging antitumor activity in pts with HR and BCG-unresponsive NMIBC with CIS. The safety profile of pembro in this pt population is consistent with that of previous studies. KEYNOTE-057 is ongoing.

Clinical trial identification

NCT02625961.

Legal entity responsible for the study

Merck & Co., Inc.

Funding

Merck & Co., Inc.

Editorial Acknowledgement

Medical writing and/or editorial assistance was provided by Matthew Grzywacz, PhD, of the ApotheCom pembrolizumab team (Yardley, PA, USA). This assistance was funded by Merck & Co., Inc., Kenilworth, NJ, USA.

Disclosure

R. de Wit: Consultancy: Sanofi, Merck, Roche; Speaker fees: Sanofi, Merck. G.S. Kulkarni: Advisory board member: Ferring, Janssen, Astellas, Amgen, Bayer, Theralase. Research funding: Biosyent. Honoraria: Abbvie, TerSera. Travel expenses, including accommodations: Abbvie, Sanofi, TerSera, Bayer. E.A. Singer: Research funding: Astellas/Medivation. L. Krieger: Advisory board member: Bayer, AstraZeneca, BMS, MSD, Roche, Janssen, Ipsen, Novartis, Pfizer, Astellas Speakers' bureau: MSD, Bayer, BMS, Ipsen Honoraria: Bayer, Ipsen, BMS, Novartis, Janssen, Astellas, MSD Travel expenses: Astella, Ipsen, Roche, MSD. P. Grivas: Honoraria: Merck & Co.; Genentech; Bristol-Myers Squibb; AstraZeneca; EMD Serono; Clovis Oncology; Seattle Genetics; Foundation Medicine; Driver Inc. D. Bajorin: Advisory board member: Merck, Genentech, Bristol Myers Squibb, Urogen, Novartis; Research funding: Merck, Novartis. A. Kamat: Research funding: FKD, Merck, Telesta, Adolor. Honoraria TMC Innovation, Merck, BMS, Arquer, MDxHealth, Photocure, Theralase, Cepheid, Medac, Asieris, Pfizer, Astra Zeneca. E. Kapadia, K. Nam, T. Frenkl: Employee and stockholder: Merck & Co., Inc. A. Balar: Advisory board member: Genentech, Merck, Incyte, AstraZeneca, Seattle Genetics, Pfizer/EMD Serono. Research funding: Genentech, Merck, AstraZeneca. Honoraria: Merck, AstraZeneca, Genentech. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings